YMYong Ma

Yong Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong Ma has a total of 180 co-authors. Here are the top co-authors by number of shared publications:

  • Chaoqun Wang

    Key Laboratory of Hepatosplenic Surgery Ministry of Education The First Affiliated Hospital of Harbin Medical University Harbin China

    27 shared publications
  • Shounan Lu

    Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    27 shared publications
  • Bing Yin

    Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    25 shared publications
  • Xinglong Li

    Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    24 shared publications
  • Shanjia Ke

    Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    23 shared publications
  • Baolin Qian

    Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    22 shared publications

Latest Publications

  • Open Access

    RGS16 Aggravates Hepatic Ischemia‐Reperfusion Injury via Hepatocyte‐Intrinsic Apoptosis/Inflammation & Neutrophil Recruitment/NETosis

    by Xinglong Li, Zhanzhi Meng, Hongjun Yu, Yongliang Hua, Zihao Li, Bing Yin, Baolin Qian, Zhongyu Li, Yongzhi Zhou, Zhigang Feng, et al.

    Hepatic ischemia–reperfusion injury (HIRI) is a frequent and severe complication after liver transplantation and hepatectomy, driven by sterile inflammation and lacking effective therapies. Regulator of G‐protein signaling 16 (RGS16) is an inflammatory modulator, but its role in HIRI remains unclear. We found that RGS16 expression was markedly increased in the livers of post‐hepatectomy patients and positively correlated with neutrophil extracellular trap formation (NETosis). Using hepatocyte‐specific Rgs16 knockout and transgenic mouse models, we demonstrated that Rgs16 deficiency attenuated hepatic inflammation and apoptosis after HIRI, whereas Rgs16 overexpression significantly exacerbated liver injury. Integrated multi‐omics analyses, including RNA‐seq, MeRIP‐seq, and mass spectrometry, identified C‐X‐C motif chemokine ligand 1 (CXCL1) as a key downstream effector of RGS16. Mechanistically, RGS16 competitively binds YTH domain family protein 3 (YTHDF3), displacing poly(A)‐nuclease deadenylation complex subunit 3 (PAN3) and stabilizing m 6 A‐modified Cxcl1 mRNA, thereby enhancing CXCL1 expression. Elevated CXCL1 promotes hepatocyte apoptosis and inflammation through C‐X‐C chemokine receptor 2 (CXCR2) and drives neutrophil recruitment and NETosis. Pharmacological inhibition of CXCL1 or degradation of NETs with DNase I significantly alleviated RGS16‐induced liver injury. Collectively, RGS16 aggravates HIRI by amplifying hepatocyte‐intrinsic CXCL1–CXCR2 signaling and CXCL1‐mediated neutrophil recruitment and NETosis, suggesting RGS16 and its downstream pathways as potential therapeutic targets for HIRI.

  • Open Access

    Cancer‐Associated Fibroblasts Promote Tumor Immunosuppression in Hepatocellular Carcinoma via the NNMT‐ANGPTL4 Axis

    by Shounan Lu, Shanjia Ke, Hongjun Yu, Zhanzhi Meng, Miaoyu Bai, Yanan Xu, Hui Zhu, Jinwen Yang, Baolin Qian, Bing Yin, et al.

    Background & Aims : Cancer‐associated fibroblasts (CAFs) drive immunosuppression in hepatocellular carcinoma (HCC). However, their metabolic regulation remains poorly defined. We investigated the role of nicotinamide N‐methyltransferase (NNMT) in CAFs. Approach & Results : High NNMT expression in CAF tissues was confirmed by western blotting and immunofluorescence staining. Primary CAFs from HCC patients, single‐cell RNA‐seq (GSE149614), patient‐derived organoids (PDOs), and fibroblast‐specific NNMT‐knockout mice were integrated by metabolomic analyses. NNMT in CAFs binds EZH2 and impedes its nuclear translocation, thereby reducing H3K27me3 enrichment at the promoter of angiopoietin‐like 4 (ANGPTL4) to increase ANGPTL4 secretion. Secreted ANGPTL4 engages GLUT1 in HCC cells, activating aerobic glycolysis and increasing histone H3K18la levels. This epigenetic reprogramming transcriptionally upregulates PD‐L1 expression, thereby facilitating tumor immune evasion. Additionally, CAF‐derived ANGPTL4 promotes angiogenesis in HCC. Therapeutically, targeting the NNMT‐ANGPTL4 axis restored CD8 + T‐cell activity and synergized with anti‐PD‐L1 therapy in both patient‐derived xenografts (PDXs) and fibroblast‐specific NNMT‐knockout murine models. Conclusion : We identified an NNMT‐ANGPTL4‐driven metabolic‐epigenetic cascade in CAFs that induces PD‐L1‐mediated immune evasion, providing a therapeutic strategy to overcome resistance to immunotherapy in patients with HCC.


  • Open Access

    Identifying shared hub genes in LIRI and MASLD through bioinformatics analysis and machine learning

    by Yongzhi Zhou, Bing Yin, Yang Yang, Zhongyu Li, Zhanzhi Meng, Shounan Lu, Baolin Qian, Xinglong Li, Yongliang Hua, Hongjun Yu, et al.

    Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are more susceptible to liver ischemia-reperfusion injury (LIRI), complicating liver surgery outcomes. This study aimed to uncover shared hub genes and mechanisms linking LIRI and MASLD to enhance donor liver utilization and improve prognosis. Using liver transplantation and MASLD datasets from the Gene Expression Omnibus, we applied Linear Models for Microarray Data and weighted gene co-expression analysis to identify differentially expressed genes and key module genes. Further analysis involved Gene Ontology, KEGG, and machine learning to pinpoint common hub genes and pathways. We identified 5,920 differentially expressed genes in liver datasets and 8,978 across LIRI and MASLD datasets. 71 shared hub genes were associated with pathways like MAPK signaling. Key genes, ADRB2 and CCL2, exhibited correlated mRNA expression in both datasets and human liver tissues. Hypoxia-reoxygenation in MASLD models elevated CCL2 levels and reduced ADRB2 expression. These genes showed strong diagnostic potential (AUC, 0.97). CCL2 knockdown reduced, while ADRB2 knockdown increased, MASLD cells’ H/R injury sensitivity. Immune infiltration analysis revealed increased immune cell activity, particularly correlations between M0/M2 macrophages and NK cells/mast cells. ADRB2 and CCL2 were identified as crucial biomarkers, potentially explaining MASLD patients’ heightened vulnerability to LIRI during liver transplantation.


  • Open Access

    NNMT/1-MNA protects against hepatic ischemia-reperfusion injury through the AKT/FOXO1/ANGPT2/JNK axis

    by Bing Yin, Baolin Qian, Hongjun Yu, Shanjia Ke, Zihao Li, Yongliang Hua, Shounan Lu, Chaoqun Wang, Mengxin Li, Sixun Guo, et al.

    Hepatic ischemia‒reperfusion injury (HIRI) occurs during liver surgery, contributing to postoperative complications such as liver failure, prolonged hospital stays, and increased morbidity and mortality rates. Yet, the mechanism underlying HIRI remains unclear. Nicotinamide N-methyltransferase (NNMT) facilitates the conversion of nicotinamide into N1-methylnicotinamide (1-MNA) and plays crucial roles in various pathophysiological processes. In this study, we find a decrease in hepatic NNMT expression and serum 1-MNA levels during HIRI. Both NNMT overexpression and exogenous 1-MNA treatment alleviate HIRI in male mice HIRI models and primary hepatocytes H/R models. Mechanistically, NNMT/1-MNA plays key roles in inflammation, apoptosis, and vascular injury during HIRI through the AKT/FOXO1/ANGPT2/JNK axis. Hepatic-specific depletion of NNMT leads to increased ANGPT2 expression and exacerbates HIRI, effects that can be mitigated by ANGPT2 knockdown. Our findings suggest that NNMT/1-MNA/ANGPT2 may regulate HIRI via the JNK signaling pathway. In summary, we present the function of NNMT and its underlying mechanism in liver injury, providing potential new therapeutical strategies for addressing HIRI.


  • Open Access

    Axin formation inhibitor 1 aggravates hepatic ischemia‒reperfusion injury by promoting the ubiquitination and degradation of PPARβ

    by Baolin Qian, Bing Yin, Hongjun Yu, Chaoqun Wang, Shounan Lu, Shanjia Ke, Zihao Li, Xinglong Li, Yongliang Hua, Zhongyu Li, et al.

    Hepatic ischemia‒reperfusion injury (HIRI) is a common pathological phenomenon after hepatectomy and liver transplantation. Here, we aim to explore the role of Axin formation inhibitor 1 (Axin1) in HIRI. In this work, we find that the expression of Axin1 is upregulated after HIRI. Cellular experiments confirme that Axin1 knockdown alleviated hypoxia/reoxygenation (H/R)-induced inflammation and apoptosis. Subsequently, we construct a HIRI model based on transgenic hepatocellular-specific Axin1 knockout and overexpression male mice and find that Axin1 deletion alleviated inflammation and apoptosis. Transcriptome sequencing reveal that the genes whose expression differed after Axin1 overexpression are significantly enriched in the PPAR signaling pathway. Furthermore, we demonstrate that Axin1 negatively regulates the expression of PPARβ, thereby activating the NF-κB pathway. Mechanistically, Axin1 binds to PPARβ to enhance the ubiquitination-mediated degradation of PPARβ by the E3 ubiquitin ligase RBBP6. Notably, adenovirus-mediated Axin1 knockdown block I/R damage in mice. Our study results demonstrate that Axin1 exacerbates HIRI by promoting the ubiquitination and degradation of PPARβ, which in turn activates the NF-κB signaling pathway. These results suggest that Axin1 may be a potential therapeutic target for HIRI.


  • GRINA alleviates hepatic ischemia‒reperfusion injury-induced apoptosis and ER-phagy by enhancing HRD1-mediated ATF6 ubiquitination

    by Hongjun Yu, Chaoqun Wang, Baolin Qian, Bing Yin, Shanjia Ke, Miaoyu Bai, Shounan Lu, Yanan Xu, Zhigang Feng, Zihao Li, et al.


  • Open Access

    Arsenic trioxide preconditioning attenuates hepatic ischemia- reperfusion injury in mice: Role of ERK/AKT and autophagy

    by Chaoqun Wang, Hongjun Yu, Shounan Lu, Shanjia Ke, Yanan Xu, Zhigang Feng, Baolin Qian, Miaoyu Bai, Bing Yin, Xinglong Li, et al.

    Background: Arsenic trioxide (ATO) is indicated as a broad-spectrum medicine for a variety of diseases, including cancer and cardiac disease. While the role of ATO in hepatic ischemia/reperfusion injury (HIRI) has not been reported. Thus, the purpose of this study was to identify the effects of ATO on HIRI. Methods: In the present study, we established a 70% hepatic warm I/R injury and partial hepatectomy (30% resection) animal models in vivo and hepatocytes anoxia/reoxygenation (A/R) models in vitro with ATO pretreatment and further assessed liver function by histopathologic changes, enzyme-linked immunosorbent assay, cell counting kit-8, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. Small interfering RNA (siRNA) for extracellular signal-regulated kinase (ERK) 1/2 was transfected to evaluate the role of ERK1/2 pathway during HIRI, followed by ATO pretreatment. The dynamic process of autophagic flux and numbers of autophagosomes were detected by green fluorescent protein-monomeric red fluorescent protein-LC3 (GFP-mRFP-LC3) staining and transmission electron microscopy. Results: A low dose of ATO (0.75 μmol/L in vitro and 1 mg/kg in vivo ) significantly reduced tissue necrosis, inflammatory infiltration, and hepatocyte apoptosis during the process of hepatic I/R. Meanwhile, ATO obviously promoted the ability of cell proliferation and liver regeneration. Mechanistically, in vitro studies have shown that nontoxic concentrations of ATO can activate both ERK and phosphoinositide 3-kinase-serine/threonine kinase (PI3K-AKT) pathways and further induce autophagy. The hepatoprotective mechanism of ATO, at least in part, relies on the effects of ATO on the activation of autophagy, which is ERK-dependent. Conclusion: Low, non-toxic doses of ATO can activate ERK/PI3K-AKT pathways and induce ERK-dependent autophagy in hepatocytes, protecting liver against I/R injury and accelerating hepatocyte regeneration after partial hepatectomy.


  • Open Access

    Genome-wide analysis of alternative splicing differences in hepatic ischemia reperfusion injury

    by Yongliang Hua, Xinglong Li, Bing Yin, Shounan Lu, Baolin Qian, Yongzhi Zhou, Zhongyu Li, Zhanzhi Meng, Yong Ma

    Alternative splicing (AS) contributes to transcript and protein diversity, affecting their structure and function. However, the specific transcriptional regulatory mechanisms underlying AS in the context of hepatic ischemia reperfusion (IR) injury in mice have not been extensively characterized. In this study, we investigated differentially alternatively spliced (DAS) genes and differentially expressed transcripts (DETs) in a mouse model of hepatic IR injury using the high throughput RNA sequencing (RNA-seq) analysis and replicate multivariate analysis of transcript splicing (rMATS) analysis. We further conducted Gene ontology (GO) term enrichment, the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and the protein-protein interaction (PPI) network. A total of 898 DAS genes (p ≤ 0.05) were screened out in the hepatic IR group compared to the sham group, while functional enrichment analysis revealed that DETs and DAS genes were significantly associated with the ATP-dependent chromain, splicesome and metabolic pathways. The expression level of the DAS genes: Gabpb2, Smg1, Tnrc6c, Mettl17, Smpd4, Kcnt2, D16Ertd472e, Rab3gap2, Echdc2 and Ssx2ip were verified by RT-PCR and qRT-PCR. Our findings provide a comprehensive genome-wide view of AS events in hepatic IR injury in mice, enhancing our understanding of AS dynamics and the molecular mechanisms governing alternative pre-mRNA splicing.